Head-To-Head Comparison: BioLargo (BLGO) vs. The Competition

BioLargo (NASDAQ:BLGO) is one of 33 publicly-traded companies in the “Chemicals & allied products” industry, but how does it contrast to its rivals? We will compare BioLargo to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Analyst Ratings

This is a summary of current ratings for BioLargo and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1250	1568	44	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 15.66%. Given BioLargo’s rivals higher possible upside, analysts clearly believe BioLargo has less favorable growth aspects than its rivals.

Profitability

This table compares BioLargo and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-591.84%	5.15%	-0.65%

Institutional & Insider Ownership

0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.3% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by insiders. Comparatively, 10.3% of shares of all “Chemicals & allied products” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares BioLargo and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-8.00
BioLargo Competitors	$6.85 billion	$211.64 million	66.88

BioLargo’s rivals have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

BioLargo has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s rivals have a beta of 1.81, meaning that their average stock price is 81% more volatile than the S&P 500.

Summary

BioLargo rivals beat BioLargo on 8 of the 10 factors compared.

About BioLargo

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.